InsiderTrades

Form 4 for RNAC Cartesian Therapeutics, Inc.

Accepted 2024-10-15 00:00:00 ET · period of report 2024-10-11 · accession 0001453687-24-000117 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2024-10-15 2024-10-11 RNAC Kalayoglu Murat Dir, 10% M - OptEx — +1.52M 4.56M +50% —
DI 2024-10-15 2024-10-11 RNAC Kalayoglu Murat Dir, 10% M - OptEx — -45.6K 56.4K -45% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-10-11 M A 1,518,373 — 4,555,260 I by trust — — (F1) On October 11, 2024, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation. (F2) Shares are held by the Trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the Trust.
2 Derivative Series A Non-Voting Convertible Preferred Stock 2024-10-11 M D 45,551.19 — 56,402.25 I by trust — · — to — 1,518,373 Common Stock (F3) On November 13, 2023, the issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023 (the "Merger"). These securities represent merger consideration payable as a result of the closing of the Merger and securities purchased in a private placement in November 2023. (F2) Shares are held by the Trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the Trust. (F1) On October 11, 2024, a trust (the "Trust") for the benefit of the reporting person's spouse and children elected to convert a portion of its shares of the issuer's Series A Non-Voting Convertible Preferred Stock into shares of the issuer's common stock. The remaining shares of the issuer's Series A Non-Voting Convertible Preferred Stock held by the Trust are subject to a beneficial ownership limitation.